Amgen Inc.
391.27USD
-1.9000 (-0.48%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 26.3B | 28.2B | 33.4B | 36.8B | 38.9B | 40.2B |
| Q1 | 6.2B | 6.1B | 7.4B | 8.1B | 8.6B | — |
| Q2 | 6.6B | 7.0B | 8.4B | 9.2B | 10.1B | — |
| Q3 | 6.7B | 6.9B | 8.5B | 9.6B | 10.0B | — |
| Q4 | 6.8B* | 8.2B* | 9.1B* | 9.9B* | 10.3B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 12.11 | 12.49 | 7.56 | 14.23 | 23.04 | 24.40 |
| Q1 | 2.68 | 5.28 | -.210 | 3.20 | 3.34 | — |
| Q2 | 2.45 | 2.57 | 1.38 | 2.65 | 4.37 | — |
| Q3 | 3.98 | 3.22 | 5.22 | 5.93 | 5.78 | — |
| Q4 | 2.99* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| 1.43* |
| 1.16* |
| 2.46* |
| 5.80 |
| — |